A surge in Aclarion, Inc. (NASDAQ: ACON) stock is currently dominating the US stock landscape, with the current session reporting a remarkable 29.15% increase, reaching $3.95. This upswing follows the revelation of a significant partnership, marking a pivotal moment for Aclarion.
Today, Aclarion (ACON) officially disclosed the execution of a strategic partnership agreement, formalizing a prior non-binding Letter of Intent (“LOI”) with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).
The collaboration harnesses ATEC’s AlphaInformatiX platform’s unique structural insights and combines them with Aclarion’s Nociscan solution, leveraging innovative biomarker data to identify potentially painful discs. This integration aims to provide surgeons with an unprecedented, comprehensive platform, enhancing clinical outcomes and reducing procedural costs for chronic low back pain (cLBP) patients.
The agreement outlines a multi-step strategic partnership wherein ATEC and Aclarion commit to collaboratively identify key opinion leader (KOL) surgeons for Nociscan technology evaluation. Surgeon feedback will guide clinical assessments, evaluating the utility of Nociscan alongside EOS imaging, the foundation of ATEC’s AlphaInformatiX platform.
Upon positive outcomes, ATEC and Aclarion plan to co-market Nociscan in targeted markets. In exchange for exclusive distribution rights, Aclarion will grant ATEC select access to its surgeon network for Nociscan evaluation and advancement within an integrated procedural solution.
Both companies have already designated internal leaders and resources for the initial phase, emphasizing the significance of biochemical markers in progressing toward shared objectives of advancing technologies in spine patient care. Nociscan, Aclarion’s proprietary decision-support tool, represents the first evidence-supported SaaS platform enabling physicians to noninvasively differentiate between painful and nonpainful discs in the lumbar spine.
By objectively quantifying chemical biomarkers associated with disc pain, Nociscan, when integrated with other diagnostic tools, offers crucial insights into the precise location of a patient’s low back pain, empowering physicians to optimize treatment strategies with clarity.
